Stay informed. See MDA updates on COVID-19

Medical Educational Resource

We're accelerating the delivery of treatments and cures.

Transition in Patients with Treatable Disorders without Fixed Weakness or Who Experience Slowly Progressive Symptoms around the Age of Transition

Activity Snapshot

Activity Type: 
On-Demand Webinar
Release Date: 
Monday, February 24, 2020
Expiration Date: 
Thursday, February 23, 2023
Sponsor Information: 

This activity has received an educational grant from PTC Therapeutics Inc.

Faculty

John Brandsema, MD
John Brandsema, MD
Neuromuscular Section Head, Division of Neurology
Children’s Hospital of Philadelphia
Lauren Elman, MD
Lauren Elman, MD
Associate Professor of Neurology
Perelman School of Medicine at the University of Pennsylvania
Vanessa Battista, MS, RN, CPNP-PC, CHPPN
Vanessa Battista, MS, RN, CPNP-PC, CHPPN
Nurse Practitioner
The Children's Hospital of Philadelphia Neuromuscular Program
Sarah Clark Stoney, MSW, LSW
Sarah Clark Stoney, MSW, LSW
Licensed Medical Social Worker (Subspecialty Outpatient Neurology Social Worker)
The Children’s Hospital of Philadelphia
Cynthia Clyburn, LSW
Cynthia Clyburn, LSW
Licensed Social Worker
Hospital of the University of Pennsylvania, Department of Neurology
Transition in Patients with Treatable Disorders without Fixed Weakness or Who Experience Slowly Progressive Symptoms around the Age of Transition
Activity Overview: 

The transition from pediatric to adult care is a challenging time for patients with neuromuscular disease and their families, as well as for providers. Increased use of disease-modifying treatments will likely lead to increased numbers of patients going through the transition process, and providers need to be aware of best practices to ensure this process is beneficial to all stakeholders. Part three of this series will focus on neuromuscular disease patients who have treatable disorders without fixed weakness or who experience slowly progressive symptoms around the age of transition.

Learning Objectives: 
  • Provide education on how advances in care have impacted, and have the potential to impact, clinical outcomes in patients with neuromuscular disease
  • Review available evidence on unmet needs in care transition and provide guidance on best practices for transitioning care in patients with:
    • Slowly progressive diseases
    • Treatable disorders without fixed weakness
  • Provide guidance on multidisciplinary care needs during this transition that are specific to the patient’s disease characteristics
  • Identify the benefits of genetic testing prior to transitioning to adult care
  • Identify clinical scenarios that can impact the process of transitioning between care settings
Accreditation and Designation Statement: 

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of PeerPoint Medical Education Institute, LLC and Muscular Dystrophy Association. The PeerPoint Medical Education Institute, LLC is accredited by the ACCME to provide continuing medical education for physicians.

The PeerPoint Medical Education Institute, LLC designates this enduring material activity for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Release Date: February 24, 2020
Expiration Date: February 23, 2023

How to Obtain CME credits : 

Once you have viewed the program, MDA will share back with you instructions for how to obtain your CME credits. If you have questions on this process, please reach out to cmemanagement@mdausa.org.

Faculty Disclosures: 

The following presenters, planners, editors, or staff have relevant financial relationships to disclose:

“I, or an immediate family member, have at present or have had within the last 12 months, the following affiliation with one or more organizations that could be perceived as a real or apparent conflict of interest in context to the design, implementation, presentation, evaluation, etc. of CME Activities.”

Ms. Vanessa Battista:

AveXis- Zolgensma; Advisory board participation, Honoraria and travel expenses

Dr. John Brandsema:

Biogen, AveXis, Cytokinetics, PTC, Sarepta, Pfizer, Fibrogen, Alexion; Advisory boards, Speakers' Bureau (Biogen), Contracted research, Consulting fees

All other presenters, planners, editors, or staff reported no relevant relationships with the following statement:

“I, or an immediate family member, do not have at present, or within the last 12 months, nor anticipate having financial interest, arrangement or affiliation with any organizations that could be perceived as a real or apparent conflict of interest in context to the design, implementation, presentation, evaluation, etc. of CME Activities.”

Copyright 2021 Muscular Dystrophy Association. All rights reserved. The Medical Education Program(s) in their entirety (including, but not limited to: webinar(s), speaker deck presentation(s), MDA Monthly Report content and case studies) are owned by Muscular Dystrophy Association and the associated partner(s) and may not be copied, reproduced, or altered in any manner without MDA’s prior written consent except that the User(s) may download, view, or use these program(s) for educational purposes only.

The Terms of Use permit User(s) to use the Medical Education Program(s) for personal and/or public education only. A User may download the information to share but will not be permitted to alter the information in any way. The User(s) is permitted to educate on one or all sections of the program(s). Any appropriate use of content available from the Medical Education Program(s) must not remove any trademarks, copyright, or any other notice contained in such content.

If you wish to alter any of the Medical Education Program(s) presented by the MDA in a form other than what is set out on mda.org, please consult meded@mdausa.org.